Stryker Co. (NYSE:SYK) Shares Sold by Flossbach Von Storch AG

Flossbach Von Storch AG cut its position in shares of Stryker Co. (NYSE:SYK) by 1.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 508,225 shares of the medical technology company’s stock after selling 6,629 shares during the period. Stryker accounts for 0.7% of Flossbach Von Storch AG’s holdings, making the stock its 28th biggest position. Flossbach Von Storch AG’s holdings in Stryker were worth $152,193,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of SYK. Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Stryker by 3.0% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 10,979 shares of the medical technology company’s stock valued at $3,295,000 after purchasing an additional 322 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in Stryker by 7.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 34,107 shares of the medical technology company’s stock valued at $10,214,000 after buying an additional 2,468 shares during the last quarter. Oakworth Capital Inc. increased its position in Stryker by 1.7% during the fourth quarter. Oakworth Capital Inc. now owns 5,908 shares of the medical technology company’s stock worth $1,769,000 after buying an additional 100 shares in the last quarter. Tyche Wealth Partners LLC acquired a new position in shares of Stryker in the fourth quarter worth $417,000. Finally, HealthInvest Partners AB purchased a new stake in shares of Stryker in the fourth quarter valued at $3,834,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 0.5 %

SYK traded down $1.63 on Wednesday, reaching $336.03. 1,056,153 shares of the company’s stock were exchanged, compared to its average volume of 1,252,351. The company has a market cap of $127.85 billion, a price-to-earnings ratio of 40.73, a PEG ratio of 2.73 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company’s 50 day moving average is $350.57 and its 200-day moving average is $312.03.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 EPS. Equities analysts predict that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is presently 38.79%.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock valued at $72,845,768 over the last quarter. Company insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

SYK has been the subject of several analyst reports. Roth Mkm boosted their target price on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Evercore ISI upped their price objective on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Truist Financial raised their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research report on Wednesday, January 31st. Citigroup boosted their price target on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, Royal Bank of Canada raised their price objective on Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $339.22.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.